KBI Biopharma Invests $30M for Expansion projects of Durham and Boulder sites

KBI Biopharma announced that they have planned to invest $30M for expanding its biopharmaceutical manufacturing capacity at both its Durham, NC, and Boulder, CO, facilities.

KBI is building commercial mammalian cell culture manufacturing capability within its Durham facility, which also houses cGMP cell culture manufacturing lines for clinical production. KBI’s development capabilities and track record of success in clinical bulk drug substance manufacturing are the foundation for its expansion into commercial production. Upon completion of the project, the commercial manufacturing line will include 2 X 2000L single-use bioreactors and a full complement of recovery and downstream purification suites which will augment the facility’s already robust process development, analytical and formulation development services.

In Boulder, KBI currently offers commercial manufacturing capacity for microbial processes at 1500L scale, and is now building a second complete manufacturing train with 300L scale fermentation capability, which leverages single use technologies. This additional, smaller-scale capacity will ensure that KBI can continue to meet the process development and clinical manufacturing needs of its clients, as well as commercial manufacturing needs for low-dose microbial products.

KBI president, Tim Kelly said that these expansions support their vision for growth and create the opportunity to better serve their customers in all areas of the biopharmaceutical industry. They are increasing their capacity for existing offerings and expanding into emerging technologies which will enable KBI to serve as a true partner and trusted advisor to their clients as their industry continues to grow.